GENELUX Corp 8-K

What Happened

• On March 19, 2026, Genelux Corporation (GNLX) filed an 8-K disclosing a Sales Agreement with TD Securities (USA) LLC (TD Cowen) under which the company may offer and sell up to $100,000,000 of its common stock. The offering will be made under the company’s existing Form S-3 registration (File No. 333-276847) and a prospectus supplement filed the same day. The company is not obligated to sell any shares and may suspend or terminate sales at any time.

Key Details

• Maximum aggregate offering size: up to $100,000,000 of common stock.
• Sales agent: TD Securities (USA) LLC (TD Cowen); compensation up to 3.0% of gross proceeds on shares sold.
• Offering method: at-the-market transactions, block trades, Nasdaq trades or other lawful methods permitted under Rule 415.
• Intended use of proceeds: general corporate purposes, including R&D, clinical trial expenses, capital expenditures and working capital.

Why It Matters

• This Sales Agreement gives Genelux a flexible, on-demand way to raise capital quickly as market conditions allow, which can fund development and operations without negotiating a single large equity financing upfront.
• Any sales under the program would dilute existing shareholders proportionally as new shares are issued; the actual dilution and timing depend on if and when the company sells shares and at what prices.
• Fees (up to 3% to TD Cowen) and market pricing will affect net proceeds; the company is not required to sell, so this is an available capital tool rather than a commitment to raise the full amount.